NextGen Bioscience, Inc.
NASDAQ : NXGBE

NextGen Bioscience, Inc.

January 21, 2008 08:00 ET

Dr. Rolf Witte Joins Scientific Advisory Board at NextGen Bioscience, Inc.

LONDON, UNITED KINGDOM--(Marketwire - Jan. 21, 2008) - NextGen Bioscience, Inc. ("NextGen") (NASDAQ:NXGBE), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced that Dr. Rolf Witte of Germany is joining its Scientific Advisory Board.

"Dr. Witte's 20 years of financial experience and his specialized expertise in investing in new biotechnologies will make an excellent addition to our Scientific Advisory Board," said Konstantinos Kardiasmenos, CEO of NextGen. "Dr. Witte's contributions will form a strategic link to the financial and private equity industries for NextGen."

About Dr. Rolf Witte

Dr. Rolf Witte is Founder, Partner and CEO of fundamenta CAPITAL AG based in Leverkusen Germany. fundamenta is a hands-on investment fund focused in the Biotech, Pharma, Medical Device and new technology sectors. Rolf is also Chief Financial Officer of CMI GmbH, a contract medical device company based in Dresden, Germany.

Prior to founding fundamenta, Dr. Witte was CEO of Pegasus Beteiligungen AG, a publicly traded investment fund. Other past positions include numerous CFO positions of European textile companies, a position with Hannover Reinsurance, and work as a lawyer specialising in audit and tax advice. As a result of his illustrious career, Dr. Witte has a thorough knowledge of the public funding in Germany and has been successful in raising over $200 million for a number of biotech companies.

Dr. Witte's academic background includes degrees in Economics and Law, Dipl. Kfm. and Ass. iur., as well as a Ph.D. in tax law from the University of Goettingen. He also was awarded a research fellowship by the DFG (Deutsche Forschungs Gemeinschaft) for researching VAT harmonization at the European Commisson in Brussels.

About NextGen Bioscience, Inc.

NextGen is positioning itself to be the world's leading bioscience company in the development and commercial licensure of novel therapeutic proteins that disrupt the advance of life-threatening cancers, with a focus on prostate and breast cancer. The company plans to leverage cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical companies.

NextGen's business model is based on recent discoveries that indicate that most tumors are derived from a single cancer-initiating cell having stem cell properties (a cancer stem cell). So far, cancer stem cells have been described as originators of malignant diseases as diverse as leukemia, breast, brain, bone, lung, melanoma, prostate, and gastrointestinal cancer. NextGen has chosen to concentrate on identification of cell-specific characteristics, making it possible to identify precursor lesions of tumors, and then conduct a full fingerprinting profile that will enable the development of cell-specific cytotoxic treatments. This will result in a 'tailor made' cancer treatment strategy that is superior to existing therapies in its ability to eradicate malignant cells whilst leaving healthy tissue intact.

For more information about NextGen Bioscience, Inc., or to schedule and interview with Mr. Kardiasmenos, please contact Graham May at +44 207 297 8186 or info@nextgenbioscience.com.

Contact Information